Video
Dr. Adam J. Gadzinski describes the emergence of precision medicine in prostate cancer
Author(s):
Urologist Adam J. Gadzinski, MD, MS, shares his excitement about the dawn of the precision medicine era in prostate cancer.
Video Player is loading.
In this video, Adam J. Gadzinski, MD, MS, highlights how precision medicine in prostate cancer was a key topic at the 2020 Society of Urologic Oncology Annual Meeting and marks the next great leap forward in the field. Gadzinski is an acting instructor of urologic oncology at the Urology Clinic at the University of Washington Medical Center.
Related Videos
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jim Hu, MD, on urinary continence recovery across RARP techniques
Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
Special Report: Tips for PCPs on evaluating prostate cancer risk
Special Report: Tailoring prostate cancer care for older adults
Special Report: New strategies emerge for metastatic prostate cancer
Special Report: Biden’s prostate cancer diagnosis renews focus on screening guidelines
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment options
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Related Content
